Literature DB >> 6208356

Characteristics of the binding of [3H]nitrendipine to rabbit ventricular membranes: modification by other Ca++ channel antagonists and by the Ca++ channel agonist Bay K 8644.

R A Janis, J G Sarmiento, S C Maurer, G T Bolger, D J Triggle.   

Abstract

This study was carried out to characterize [3H]nitrendipine binding to cardiac membranes and to test the hypothesis that high affinity binding of Ca++ channel antagonists and agonists is to Ca++ channels. Binding was specific, rapid, reversible and stereoselective. The relative order of potency of nifedipine analogs for inhibition of binding was the same as that for inhibition of smooth and cardiac muscle contraction. Results with diltiazem, verapamil and lidoflazine were consistent with the hypothesis that nondihydropyridine Ca++ channel antagonists act at one or more sites allosterically linked to the 1,4-dihydropyridine site in cardiac cells. The Ca++ channel agonist Bay K 8644 [methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyr idine- 5-carboxylate] displaced specifically bound [3H]nitrendipine in an apparently competitive manner with an IC50 value of 5 nM. The results suggest that organic antagonists do not act by physically blocking the Ca++ channel. The data also support the hypothesis that the high affinity binding sites for [3H]nitrendipine in isolated cardiac membranes are associated with Ca++ channels that are inactivated or are otherwise unavailable for opening.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208356

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Calcium channel antagonists: pharmacological considerations.

Authors:  D Rampe; C M Su; F Yousif; D J Triggle
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

2.  Inotropic effects of Ca2+ channel agonist and antagonists in neuraminidase-treated left atria of rats.

Authors:  Y Hattori; S Hazama; M Kanno; Y Nakao
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

3.  Involvement of calcium channels in the contractile activity of neurotensin but not acetylcholine: studies with calcium channel blockers and Bay K 8644 on the rat fundus.

Authors:  M V Donoso; J P Huidobro-Toro; A Kullak
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

4.  The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.

Authors:  H-L Zhu; T Tomoda; M Aishima; Y Ito; N Teramoto
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

5.  Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activators related to Bay K 8644 in smooth muscle, cardiac muscle and neuronal preparations.

Authors:  Y W Kwon; G Franckowiak; D A Langs; M Hawthorn; A Joslyn; D J Triggle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

6.  Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure.

Authors:  T Ankermann; U Osterkamp; S R Santos; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Investigation of the negative inotropic effects of 17 beta-oestradiol in human isolated myocardial tissues.

Authors:  G Sitzler; O Lenz; H Kilter; K La Rosee; M Böhm
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

8.  Effect of selective agonists and antagonists on atrial adenosine receptors and their interaction with Bay K 8644 and [3H]-nitrendipine.

Authors:  P A Borea; L Caparrotta; M De Biasi; G Fassina; G Froldi; L Pandolfo; E Ragazzi
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

Review 9.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

10.  Bioavailability and elimination of nitrendipine in liver disease.

Authors:  P Dylewicz; W Kirch; S R Santos; H J Hutt; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.